cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Stockal+Disclaimer.pdf
9 own
17 watching
Current Price
$1.99
$-0.03
(-1.49%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
125.37M
52-Week High
52-Week High
3.29000
52-Week Low
52-Week Low
1.11000
Average Volume
Average Volume
0.09M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization125.37M
icon52-Week High3.29000
icon52-Week Low1.11000
iconAverage Volume0.09M
iconDividend Yield--
iconP/E Ratio--
What does the Stockal+Disclaimer.pdf do?
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber s congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as ProQR Therapeutics VIII B.V. for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Read More
News & Events about Stockal+Disclaimer.pdf.
PR Newswire
1 year ago
Thinking about buying stock in Thermogenesis Holdings, ProQR Therapeutics, Grom Social, ORIC Pharmaceuticals, or Acasti Pharma? Thinking about buying stock in Thermogenesis Holdings, ProQR Therapeutics, Grom Social, ORIC Pharmaceuticals, or Acasti Pharma? PR Newswire NEW YORK, Dec. 22, 2022 NEW...
Globe Newswire
1 year ago
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that ProQR management will host an investor conference call and webcast to discuss the...
PR Newswire
1 year ago
Lilly and ProQR to Expand RNA Editing Collaboration Lilly and ProQR to Expand RNA Editing Collaboration PR Newswire INDIANAPOLIS and LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 22, 2022 New agreement supports the discovery and development of additional assets directed toward high conviction...
Globe Newswire
1 year ago
New agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQRs Axiomer technologyINDIANAPOLIS; LEIDEN, Netherlands; and CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V...
Ticker Report
1 year ago
StockNews.com downgraded shares of ProQR Therapeutics (NASDAQ:PRQR Get Rating) from a hold rating to a sell rating in a research report released on Friday morning. Other equities analysts have also issued reports about the stock. Cantor Fitzgerald lowered shares of ProQR Therapeutics from an...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$1.99
$-0.03
(-1.49%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00